Table 3.
Efficacy Outcomes Following Treatment With Artemisinin-Based Combination Therapies
| Efficacy Outcomes | PROMOTE |
TCC |
|
|---|---|---|---|
| AL (n = 572) | AL (n = 201) | DP (n = 165) | |
| Fever clearancea, No. (%) | |||
| Fever on day 1 | 200 (35.2) | 106 (53.0) | 46 (40.6) |
| Fever on day 2 | 39 (7.0) | 16 (8.0) | 7 (4.2) |
| Fever on day 3 | 17 (3.1) | 3 (1.5) | 5 (3.0) |
| Parasite clearance, No. (%) | |||
| Parasitemia on day 2 | 31 (5.6) | 32 (16.1) | 5 (3.0) |
| Parasitemia on day 3 | 5 (0.9) | 3 (1.5) | 1 (0.6) |
| WHO 28-day outcome, No. (%) | |||
| Lost to follow-up | 4 (0.7) | 2 (1.0) | 2 (1.2) |
| Early treatment failure | 4 (0.7) | 0 | 0 |
| Late clinical failure | 42 (7.3) | 19 (9.5) | 3 (1.8) |
| Late parasitological failure | 123 (21.5) | 53 (26.4) | 11 (6.7) |
| Adequate clinical and parasitological response | 399 (69.8) | 127 (63.2) | 149 (90.3) |
| Gametocytes detected during 28-day follow-up, No. (%) | 97 (17.0) | 15 (7.5) | 30 (18.2) |
| Hemoglobin recoveryb, g/dL, mean (SD) | 0.6 (1.2) | 0.6 (1.5) | 1.0 (1.4) |
Abbreviations: AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; SD, standard deviation; TCC, Tororo Child Cohort; WHO, World Health Organization.
a Subjective fever over previous 24 hours or temperature ≥38.0°C.
b Change in hemoglobin from day 0 to day 28 or day of clinical failure.